no scored calls yet — needs a stated position or a categorical verdict, with a matured window vs SPY
Hom said Sematic Labs uses AI to automate steps in regulatory systematic reviews, reducing a process that can take years manually to roughly four hours.
Hom said Revolution Medicines' molecular-glue therapy increased median survival in second-line metastatic pancreatic cancer from roughly seven to thirteen months, with fewer serious adverse events, and could become a baseline for combination therapies.
Unlike tech, pharma faces patent cliffs where generics erode 95% of revenue after ~20 years. Tirzepatide doing $51B sales but will decline. Manufacturing scale for $50B drugs creates moat but also capex burden. 100T biotech valuation unlikely without patent reform or new modalities.